[IDDM treatment with an insulin-expressing vector].
Islet transplantation has proven successful at delivering insulin in a regulated manner. However, the scarcities of islet donors are important limitations. The idea of engineering non-beta cell such as hepatocytes, myocytes, to produce insulin emerged at the end of 80's. To attain insulin production similarly to islet beta cell, a number of devices has been performed, including proinsulin processing and regulated secretion of insulin, resulting in functioning beta-cell surrogates to some extent. These attempts will be merged with currently on-going islet-regeneration therapies from multipotent embryonic stem (ES) cells.
Takeuchi
T
T
Institute for Molecular and Cellular Regulation, Gunma University.
D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000235:genetics*; D016381:Islets of Langerhans Transplantation; D011384:Proinsulin / Q000235:genetics
D007328:Insulin; D011384:Proinsulin